Edesa Biotech (EDSA) president buys 2,000 shares in open market

Rhea-AI Filing Summary

Edesa Biotech, Inc. President Michael J. Brooks purchased 2,000 common shares in an open-market trade at $1.57 per share on February 26, 2026. Following this transaction, he directly owns 226,870 common shares, indicating a relatively small, incremental increase in his personal stake.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brooks Michael J

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM A6 L3R 5H6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/26/2026		P		2,000	A	$1.57	226,870	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Peter J. Weiler, Attorney-in-Fact for Michael J. Brooks	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edesa Biotech (EDSA) report for Michael J. Brooks?

Edesa Biotech reported that President Michael J. Brooks bought 2,000 common shares in an open-market transaction. He paid $1.57 per share, modestly increasing his direct ownership and signaling a small additional personal investment in the company’s stock.

At what price did Edesa Biotech’s president buy the newly acquired shares?

Michael J. Brooks purchased the 2,000 Edesa Biotech common shares at $1.57 per share. This open-market price reflects what he was willing to pay to increase his stake, based on prevailing market conditions at the time of the transaction.

How many Edesa Biotech (EDSA) shares does Michael J. Brooks now own?

After the reported purchase, Michael J. Brooks directly owns 226,870 Edesa Biotech common shares. This figure includes his new 2,000-share acquisition and represents his total direct holding as disclosed in the Form 4 insider trading report.

Was the Edesa Biotech insider transaction a purchase or a sale?

The transaction was a purchase. President Michael J. Brooks executed an open-market buy of 2,000 common shares, increasing his direct holdings. There were no reported sales in this Form 4, making the overall activity a net-buy transaction.

What does an open-market purchase by Edesa Biotech’s president typically indicate?

An open-market purchase generally shows the insider choosing to spend personal funds to acquire shares. In this case, Michael J. Brooks’ 2,000-share buy modestly boosts his exposure to Edesa Biotech’s performance, although the transaction size itself is relatively small.